explore -WSS

explore

author：explore 2025-09-03 09:38:07 - browse：5

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Republican states more likely to report Covid vaccine side effects

hotspot

WSS

Trial using CRISPR to edit HIV out of cells disappoints

Multiple sclerosis has subtypes with different best treatments: study

Addiction experts warn against a second 'war on drugs'

Gut bacteria may contribute to kidney autoimmunity, study finds

Bird flu in dairy cattle: New measures to control spread to humans

Harvard scientists, with Google, unveil the most detailed brain map ever

focus

explore

entertainment

Virginia high school admissions case could be legal follow

Military medical care influenced by rank and race, new study finds

Duchenne breakthrough therapy leaves behind pioneering families

Data integrity in scientific journals requires "effort" by publishers, institutions

Hepatitis C has a cure — but many Americans still lack access to it

Insurer loopholes limit power of law against surprise medical bills

Guidelines to prevent youth baseball injuries need more muscle

Cytokinetics CEO stresses company can launch heart drug on its own

ChatGPT in medicine: STAT answers readers' burning questions

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

hotspot

Harvard scientists, with Google, unveil the most detailed brain map ever

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Florida Supreme Court upholds state's abortion ban

Mass General Brigham physicians react to latest merger step

knowledge

explore

hotspot

explore